

# Outbreak of Infections Caused by *Shigella sonnei* with Reduced Susceptibility to Azithromycin in the United States

Maria Sjölund Karlsson,<sup>a</sup> Anna Bowen,<sup>a</sup> Roshan Reporter,<sup>b</sup> Jason P. Folster,<sup>a</sup> Julian E. Grass,<sup>a</sup> Rebecca L. Howie,<sup>c</sup> Julia Taylor,<sup>c</sup> Jean M. Whitchard<sup>a</sup>

Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA<sup>a</sup>; Los Angeles County Department of Public Health, Los Angeles, California, USA<sup>b</sup>; IHRC, Inc., Atlanta, Georgia, USA<sup>c</sup>

Shigellosis is the third most common enteric bacterial infection in the United States (1). The disease is caused by *Shigella* bacteria, and symptoms include abdominal cramps, diarrhea that sometimes contains blood, nausea, vomiting, and fever. *Shigella sonnei* has a very low infectious dose, and the infection may spread from person to person or via contaminated objects, food, or water. In the United States, the incidence is highest among children who are <5 years old, and multiple outbreaks of *S. sonnei* infections have been associated with daycare centers (2, 3).

In the United States, shigellosis is frequently treated with antimicrobial drugs because they can slightly shorten the duration and severity of illness (4). Increasing resistance to ampicillin and trimethoprim-sulfamethoxazole has led physicians to prescribe azithromycin for treatment of shigellosis (3, 5). Azithromycin is currently recommended by the American Academy of Pediatrics and the Infectious Diseases Society of America for the treatment of multidrug-resistant shigellosis, although azithromycin susceptibility testing guidelines and interpretive criteria are lacking for *Shigella* (6, 7). A study by Howie et al. showed the susceptible wild-type distribution of MICs to range from 4 to 16 µg/ml (8). Isolates with higher azithromycin MICs have been confirmed to harbor *mphA*, a macrolide resistance gene encoding a macrolide-2'-phosphotransferase (8, 9).

In May 2012, the Los Angeles County Department of Public Health (Los Angeles County, CA) investigated an outbreak caused by *S. sonnei* that sickened 43 people. Four representative isolates (2012C-3667 to 2012C-3670) were submitted to the Centers for Disease Control and Prevention (CDC). Two isolates were ob-

tained from asymptomatic, male employees of a bridge club, one of whom was a food handler. Two isolates were obtained from women in the same club. Both women were hospitalized with nonbloody diarrhea; one was ill for 7 days and reported vomiting and fever of 102°F; the duration of illness was not reported for the other. The ages of these four individuals ranged from 60 to 89 years.

The isolates yielded indistinguishable patterns by pulsed-field gel electrophoresis (PFGE) using XbaI (PulseNet pattern J16X01.0756). Susceptibility to 14 antimicrobial agents was determined by broth microdilution (Sensititre; Trek Diagnostics, Westlake, OH). All four isolates displayed resistance to streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. In addition, all four isolates displayed azithromycin MICs of >16 µg/ml (Table 1). PCR screening confirmed the presence of *mphA* in all four isolates (8). Plasmid DNA from two isolates was electroporated into *Escherichia coli* DH10B cells. *E. coli* transformants with elevated MICs to azithromycin (MIC > 16 µg/ml) confirmed the *mphA* gene to be located on a plasmid. The plasmid type could not be determined by *inc/rep* typing (10).

To our knowledge, this is the first outbreak caused by *Shigella*

Published ahead of print 28 December 2012

Address correspondence to Maria Sjölund Karlsson, fwt4@cdc.gov.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.02360-12

TABLE 1 MICs for *Shigella sonnei* and *Escherichia coli* isolates<sup>a</sup>

Antimicrobial agent <sup>b</sup>	MIC (µg/ml) for isolate:						
	2012C-3667	2012C-3668	2012C-3669	2012C-3670	DH10B-3668	DH10B-3670	DH10B
Ampicillin	2	2	4	4	4	4	4
Amoxicillin-CLA	4	4	4	4	2	4	2
Azithromycin	>16	>16	>16	>16	>16	>16	2
Cefoxitin	2	2	2	2	8	8	8
Ceftriaxone	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25
Chloramphenicol	4	4	4	4	≤2	≤2	≤2
Ciprofloxacin	≤0.016	≤0.016	≤0.016	≤0.016	≤0.016	≤0.016	≤0.016
Gentamicin	2	1	1	1	0.5	0.5	0.5
Kanamycin	≤8	≤8	≤8	≤8	≤8	≤8	≤8
Nalidixic acid	1	1	1	1	1	1	1
Streptomycin	>64	>64	>64	>64	>64	>64	>64
Sulfisoxazole	>256	>256	>256	>256	>256	>256	≤16
Tetracycline	>32	>32	>32	>32	≤4	≤4	≤4
Trimethoprim-sulfamethoxazole	>4	>4	>4	>4	>4	>4	≤0.125

<sup>a</sup> The *Shigella sonnei* and *Escherichia coli* isolates tested were four 2012 outbreak isolates of *Shigella sonnei* (2012C-3667 to 2012C-3670), two *Escherichia coli* DH10B transformants (DH10B-3668 and DH10B-3670), and *E. coli* DH10B.

<sup>b</sup> CLA, clavulanic acid.

isolates displaying elevated azithromycin MICs to be documented within the United States. The circulation of *Shigella* isolates with high azithromycin MICs is worrisome, since it may limit the treatment options for multidrug-resistant infections, especially among children.

## REFERENCES

1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United States—major pathogens. *Emerg. Infect. Dis.* 17:7–15.
2. Arvelo W, Hinkle CJ, Nguyen TA, Weiser T, Steinmuller N, Khan F, Gladbach S, Parsons M, Jennings D, Zhu BP, Mintz E, Bowen A. 2009. Transmission risk factors and treatment of pediatric shigellosis during a large daycare center-associated outbreak of multidrug resistant *Shigella sonnei*: implications for the management of shigellosis outbreaks among children. *Pediatr. Infect. Dis. J.* 28:976–980.
3. Shiferaw B, Solghan S, Palmer A, Joyce K, Barzilay EJ, Krueger A, Cieslak P. 2012. Antimicrobial susceptibility patterns of *Shigella* isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000–2010. *Clin. Infect. Dis.* 54(Suppl. 5):S458–S463.
4. Christopher PRH, David KV, John SM, Sankarapandian V. 2010. Antibiotic therapy for *Shigella* dysentery. *Cochrane Database Syst. Rev.* 2010(8):CD006784. doi:10.1002/14651858.CD006784.pub4.
5. Basualdo W, Arbo A. 2003. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. *Pediatr. Infect. Dis. J.* 22:374–377.
6. American Academy of Pediatrics. 2012. *Shigella* infections, p 645–647. In Pickering LK, Baker CJ, Kimberlin DW, Long SS (ed), *Red book: 2012 report of the Committee on Infectious Diseases*, 29th ed. American Academy of Pediatrics, Elk Grove Village, IL.
7. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK. 2001. Practice guidelines for the management of infectious diarrhea. *Clin. Infect. Dis.* 32:331–351.
8. Howie RL, Folster JP, Bowen A, Barzilay EJ, Whichard JM. 2010. Reduced azithromycin susceptibility in *Shigella sonnei*, United States. *Microb. Drug Resist.* 16:245–248.
9. Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, Filliol I, Dhaluin A, Ifrane SA, Weill FX, Leclercq R. 2008. Macrolide-resistant *Shigella sonnei*. *Emerg. Infect. Dis.* 14:1297–1299.
10. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. *J. Microbiol. Methods* 63:219–228.